TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma; OS, overall survival; BCLC, Barcelona Clinic Liver Cancer; APASL, Asian Pacific Association for the Study of the Liver; AASLD, American Association for the Study of Liver Diseases; JSH, Japan Society of Hepatology; VEGF, vascular endothelial growth factor; PFS, progression-free survival; CT, computed tomography; MRI, magnetic resonance imaging; HR, hazard ratio; CI, confidence interval; PIVKA-II, protein induced by vitamin K absence-II; TTP, time to progression. This evidence concerns the gene VEGFA and hepatocellular carcinoma.